Lung cancer screening: tell me more about post-test risk

This is the authors' abstract. We don't add key points for this paper.

Lung cancer screening (LCS) by low-dose computed tomography (LDCT) can save lives because LC is detected in its early asymptomatic stage (1). We have come a long way since the first results of the national lung screening trial (NLST) (2), now confirmed in Europe by volumetric LDCT against control arm by the Nederlands Leuvens Longkanker Screenings Onderzoek (NELSON) (3) and the multicentric Italian lung detection (MILD) (4). The literature shows a substantial variability of LC risk even among screenees selected with strict risk criteria (5-7). Furthermore, the evolving research in LCS provides reinforced evidence on prolonged LCS for continuous and incremental reduction of lung cancer mortality In such scenario, the relentless development and optimization of LCS practice is about reduction of false positives and radiation exposure, while refining efficiency (10-15).